Table 6.

Univariate and Multivariate Analysis Between Clinicopathological Characteristics and OS of Breast Cancer Patients

	Univariate Analysis		Multivariate Analysis
	HR (95% CI)	P-value	HR (95% CI)	P-value
Age
≤45	Reference	–	Reference	–
>45	1.52 (1.08–2.13)	0.0151	1.58(1.12–2.23)	0.0096
T stage (0/1/2/3/4)	1.38 (1.17–1.63)	<0.0005	1.21 (1.03–1.42)	0.0244
Axillary lymph node
Negative	Reference		Reference
Positive	1.06 (1.01–1.12)	0.017	–
Molecular subtype
HR+/HER2-	Reference	–	Reference
HR+/HER2+	1.38(0.89–2.15)	0.1483	–	–
HR−/HER2+	1.88(1.13–3.13)	0.0152	–	–
TNBC	3.29(2.04–5.28)	<0.0001	2.671(1.7–4.198)	<0.0001
Distant metastasis
No	Reference		Reference
Yes	4.71 (2.07–11.11)	<0.0005	6.16 (2.54–14.92)	<0.0001
Surgery
No	reference		reference
Yes	0.191 (0.083–0.44)	<0.0001	0.59 (0.50–0.69)	<0.0001
Chemotherapy
No	Reference		Reference
Yes	0.65 (0.42–1.02)	0.0622	–	–
Radiation			–	–
No	Reference		Reference	–
Yes	1.62 (1.13–2.33)	0.0089	1.66 (1.17–2.36)	0.0461
Endocrine therapy
No	Reference		Reference	–
Yes	0.59(0.43–0.83)	<0.0005	–	–
HR change
HR+/HER2−/+to HR+/HER2−/+	Reference	–	Reference	–
HR+/HER2−/+ to HR-/HER2−/+	1.75(1.01–3.03)	0.047	1.78(1.02–3.1)	0.0409
HR−/HER2− to HR−/HER2−	3.21(1.74–5.90)	0.0002	2.98(1.61–5.55)	0.0005
HR−/HER2−/+ to HR+/HER2−/+	2.79(1.62–4.83)	0.0002	2.48(1.41–4.37)	0.0016

Notes: +, Means receptor expression positive; −, Means receptor expression negative.

Abbreviations: HER2, human epidermal growth factor receptor 2; HR, hormone receptor.